TY - JOUR AU - Nishino, Kazumi AU - Ohe, Shuichi AU - Kitamura, Masanori AU - Kunimasa, Kei AU - Kimura, Madoka AU - Inoue, Takako AU - Tamiya, Motohiro AU - Kumagai, Toru AU - Nakatsuka, Shin-ichi AU - Isei, Taiki AU - Imamura, Fumio PY - 2018 TI - Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lung JF - Journal of Thoracic Disease; Vol 10, No 6 (June 30, 2018): Journal of Thoracic Disease Y2 - 2018 KW - N2 - Nivolumab, a fully humanized monoclonal IgG4 antibody blocking programmed cell death-1 (PD-1), has demonstrated improved survival over docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) (1,2). Vitiligo-like depigmentation is a well described immune-related adverse event (irAE) in melanoma patients receiving immunotherapy with PD-1 inhibitors but it’s rare in NSCLC (3). We experienced a rare case of metastatic NSCLC who developed vitiligo-like lesions during nivolumab treatment after excess sunburn. We presented clinical course of this patient with the data of histological and immunohistochemical analysis of the skin lesions. UR - https://jtd.amegroups.org/article/view/21552